Shopping Cart
Remove All
Your shopping cart is currently empty
ST034307 is an effective and selective inhibitor of adenylyl cyclase 1 (IC50: 2.3 μM).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $32 | In Stock | In Stock | |
| 2 mg | $45 | In Stock | In Stock | |
| 5 mg | $74 | In Stock | In Stock | |
| 10 mg | $117 | In Stock | In Stock | |
| 25 mg | $248 | In Stock | In Stock | |
| 50 mg | $392 | In Stock | In Stock | |
| 100 mg | $629 | In Stock | In Stock | |
| 200 mg | $886 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $81 | In Stock | In Stock |
| Description | ST034307 is an effective and selective inhibitor of adenylyl cyclase 1 (IC50: 2.3 μM). |
| Targets&IC50 | AC type I:2.3 μM |
| In vitro | ST034307 obviously inhibits the forskolin- or isoproterenol-stimulated AC1 activity in HEK cells stably expressing AC1. ST034307 significantly inhibits the Ca2+/calmodulin-stimulated cAMP accumulation in the hippocampal homogenates. ST034307 dose-dependently inhibits both the development and the maintenance of the MOR-mediated sensitization of AC1. ST034307 reveals selective inhibition of AC1 and potentiates AC8 activity to a nonsignificant small extent. ST034307 potentiates phorbol 12-myristate 13-acetate (PMA)-stimulated cAMP production by AC2. ST034307 has no significant effects on wild-type HEK cells [1]. |
| In vivo | ST034307 shows an estimated median effective dose (E50) value for analgesia of 0.28 μg in the mouse pain model. ST034307 (0.25 μg) induces an obvious relief of CFA-induced inflammatory pain in mice [1]. |
| Molecular Weight | 297.95 |
| Formula | C10H4Cl4O2 |
| Cas No. | 133406-29-8 |
| Smiles | Clc1ccc2oc(cc(=O)c2c1)C(Cl)(Cl)Cl |
| Relative Density. | 1.674 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (167.81 mM), Sonication and heating are recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (3.36 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.